Back to top
more

AMN Healthcare Services (AMN)

(Delayed Data from NYSE)

$42.57 USD

42.57
740,451

-0.06 (-0.14%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $42.57 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 31% (172 out of 251)

Industry: Medical Services

Better trading starts here.

Zacks News

Masimo (MASI) Provides FY22 View, Preliminary FY21 Results Solid

Masimo's (MASI) solid full-year results likely to have been boosted by strong product sales.

Bio Rad's (BIO) Product Launches Aid, Forex Woes Persist

Bio Rad's (BIO) strength in its key product lines across major geographic regions buoys optimism.

Quest Diagnostics (DGX) Posts Preliminary Q4 & 2021 Results

Quest Diagnostics (DGX) posts preliminary fourth-quarter and full-year results, reflecting an increase in COVID-19 testing services and a steady recovery in the company's base testing volumes.

Zacks.com featured highlights include: Accenture plc, Builders FirstSource, Inc. and AMN Healthcare Services, Inc.

Accenture plc, Builders FirstSource, Inc. and AMN Healthcare Services, Inc. are included in this blog.

Integra (IART) Announces Preliminary Q4 & '21 Sales Results

Integra's (IART) preliminary revenue results and recent plans to implement a $125-million share repurchase instill investor optimism.

Here's Why You Should Retain Thermo Fisher (TMO) Stock for Now

Investors are optimistic about Thermo Fisher's (TMO) strong end-market growth and focus on international regions.

Here's Why You Should Retain Abiomed (ABMD) Stock For Now

Investors remain optimistic about Abiomed (ABMD) due to its Impella product line's strength.

Inogen's (INGN) Preliminary Q4 Revenues Solid Amid Challenges

Inogen's (INGN) revenue growth in the fourth quarter is likely to have been boosted by solid product sales despite supply chain constraints.

Cardiovascular Systems (CSII) Coronary Sales Up Amid COVID Woe

Cardiovascular Systems (CSII) continues to experience strong demand for physician training and certification in all international markets.

Hologic (HOLX) Up on Preliminary Q1 Organic Sales Growth

Hologic's (HOLX) Diagnostics division's preliminary numbers show a strong rebound in the base business.

Here's Why AMN Healthcare (AMN) Could be Great Choice for a Bottom Fisher

AMN Healthcare (AMN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

3 Stocks With Momentum Anomaly to Create a Winning Portfolio

Accenture (ACN), Builders FirstSource (BLDR) and AMN Healthcare Services (AMN) are currently witnessing a short-term pullback in price. So, make sure you take full advantage of it.

Here's Why You Should Hold on to Align Technology (ALGN) Now

Investors are optimistic about Align Technology (ALGN) given huge market potential in its Invisalign brand and strategic partnerships.

Medtronic (MDT) Gets MHLW Approval for Micra AV Sale in Japan

The Micra AV approval is likely to boost Medtronic's (MDT) Cardiac Rhythm Management business while delivering the benefits of leadless pacing in Japan.

Illumina (ILMN) Announces Preliminary Q4 Sales, Issues '22 View

Illumina's (ILMN) preliminary fourth-quarter results, latest partnership deals and a robust pipeline of technologies instill investor optimism.

AMN Healthcare Services (AMN) Gains But Lags Market: What You Should Know

AMN Healthcare Services (AMN) closed the most recent trading day at $107.50, moving +0.41% from the previous trading session.

Here's Why You Should Retain BD (BDX) Stock in Your Portfolio

Investors continue to be optimistic about BD (BDX) owing to its slew of regulatory approvals and strategic buyouts.

Quidel Corporation (QDEL) Reports Solid Preliminary Q4 Revenues

Quidel's (QDEL) revenue growth in the fourth quarter is likely to have been boosted by continued robust sales of its SARS-related products.

IDEXX's (IDXX) Low LPD Sales, Rise in Expenses Dampen Growth

Distributor purchasing dynamics have an impact on IDEXX's (IDXX) reported sales of CAG products.

DexCom (DXCM) Posts Solid Preliminary Q4 and 2021 Revenues

DexCom (DXCM) posts solid fourth-quarter and full-year 2021 revenue data on the back of resilience shown in the face of the COVID-19 induced challenges.

Here's Why You Should Retain AmerisourceBergen (ABC) Stock

AmerisourceBergen (ABC) continues to gain traction from the robust pharmaceutical segment. However, stiff competition is a woe.

Medtronic (MDT) to Buy Affera, Expand in Electrophysiology

Affera's full suite of solutions and technologies will complement Medtronic's (MDT) existing atrial and ventricular arrhythmia disease management portfolio.

Here's Why You Should Retain Intuitive Surgical (ISRG) Stock

Intuitive Surgical (ISRG) continues to gain traction from improving the adoption of the da Vince Surgical System. Higher production costs are a woe.

PacBio's (PACB) Sequel IIe Boosts Radboudumc's Sequencing Ability

PacBio's (PACB) sequencing system enhances Radboudumc's SMRT sequencing capability through the addition of two new PacBio Sequel IIe systems.

BD (BDX) Product Gets FDA Nod, Patient Outcome to Get a Boost

Regulatory clearance for BD's (BDX) Kiestra IdentifA system is expected to lead to better patient management via automated sample processing and MALDI target preparation.